MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
EYEG - Eyegate Pharmaceuticals Inc
$5.59
-0.47(-7.76%)8:54:30 PM 2/26/2021
EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye in the United States. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wounds, defects, and epitheliopathies, as well as for re-epithelization of the ocular surface. It is also developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients and anterior uveitis; and Eyegate II drug delivery system. The company has license agreements with the University of Miami School of Medicine; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
leak data

Related Topics

Peers

Related Peers

Stock news

    02/1/2021EYEG
    EyeGate Pharmaceuticals Announces Management Transition In Support of Strategic Transformation

    - Franz Obermayr, Ph.D. Appointed as Acting Chief Executive Officer, Transitioning From EVP Clinical Development - - Stephen From Elevated from Chief Executive Officer to Executive Chairman - WALTHAM, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing products for treating inflammatory and immune diseases with a focus on the eye and nervous system, today announced that Franz Obermayr, Ph.D., Man...

    01/6/2021EYEG
    EyeGate Enters Into Agreement for $8.0 Million Private Placement

    WALTHAM, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system, today announced that it has entered into a securities purchase agreement in connection with a private placement (the “Private Placement”) with an affiliate of Armistice Capital, LLC (“Armistice”) for aggregate gross pro...

    12/30/2020EYEG
    EYEG: Expanding the pipeline

    By Beth Senko, CFA NASDAQ:EYEG READ THE EYEG RESEARCH REPORT HERE EyeGate Pharmaceuticals is a late-stage clinical company developing better solutions to current treatments for post-surgical eye care and moderate to severe dry eye using OBG, its proprietary cross- linked formulation of sodium hyaluronate (HA). On December 18, 2020, EyeGate Pharmaceuticals (NASDAQ:EYEG) announced it will acquire

    12/21/2020EYEG
    Biopharma M&A Continues: Agios Sells Oncology Portfolio, NantKwest's Reverse Merger With ImmunityBio, Eyegate Picks Up Panoptes

    M&A momentum in the biopharma space picked up pace, with a few more deals announced in the space this week.Agios To Divest Oncology Portfolio: In a streamlining bid and to have a singular focus Agios Pharmaceuticals Inc (NASDAQ: AGIO) announced it's divesting its commercial and clinical-stage oncology portfolio to French biotech Servier for $2 billion.Of the total proceeds, $1.8 billion will be received as upfront cash payment and $200 million in potential future milestone payment for voraside...

    12/21/2020EYEG
    Benzinga Pro's Top 5 Stocks To Watch For Monday, Dec. 21, 2020: EYEG, NKE, ZM, WMT, AIM

    Today's 5 Stock Ideas: * Eyegate Pharmaceuticals (EYEG) \- The company announced the acquisition of Panoptes Pharma. The acquisition added to EyeGate's pipeline. Shares traded roughly 80% higher premarket today. * Nike (NKE) \- The company announced better-than-expected Q2 EPS and sales results and an increase in digital sales on Friday after the close. Shares traded roughly 4% higher premarket today. * Zoom Video (ZM) \- Shares traded roughly 4% higher premarket. This could be due to increa...

    12/21/2020EYEG
    EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma

    Expands Pipeline Beyond Ophthalmology with PP-001, a Clinical Stage, Best-in-Class DHODH Inhibitor PP-001 Leverages a Validated Immune Modulating Mechanism Optimized for Increased Specificity and Picomolar Potency to Avoid Off-Target Side EffectsAcquisition Strengthens Leadership Team with Appointment of Panoptes Co-Founders Dr. Franz Obermayr as EVP Clinical Development and Dr. Stefan Sperl as EVP CMC and OperationsWALTHAM, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc....

    11/30/2020EYEG
    EYEG: Looking Ahead to 2021

    By Beth Senko, CFA NASDAQ:EYEG READ THE FULL EYEG RESEARCH REPORT EyeGate Pharmaceuticals (NASDAQ:EYEG) is a late-stage clinical company developing better solutions to current treatments for post-surgical eye care and moderate to severe dry eye using OBG, its proprietary cross- linked formulation of sodium hyaluronate (HA). The Company is preparing its IND filing for OBG as an alternative to a

    11/9/2020EYEG
    EyeGate Pharma Reports Third Quarter 2020 Financial Results and Provides Business Update

    WALTHAM, MA / ACCESSWIRE / November 9, 2020 / EyeGate Pharmaceuticals, Inc.